A recent study has shown that the drug Cozaar is associated with an increased risk of heart attack, stroke and death in patients with diabetes, which may be related to increased cardiovascular risk in these patients.
The findings were published in the July issue ofTheJournal of the American Medical Association.
Study
The results were presented at the annual meeting of the American Society of Nephrology, which is sponsored by GlaxoSmithKline Pharmaceuticals. The study was presented at an annual meeting in Boston on August 19.
Figure 1: The Cozaar association with a cardiovascular risk.
Cozaar, also known as losartan, is a prescription antihypertensive medication that has been used for many years in the management of hypertension. The drug has been used for many years to lower blood pressure by reducing blood pressure by inhibiting the action of certain vasoconstrictors in the heart.
A meta-analysis published in the December issue ofAnnual Reviews of Cardiac Carefound that patients with hypertension who were taking Cozaar had an increased risk of developing cardiovascular death. The study's authors concluded that the increased risk is likely related to the drug's mechanism of action, which is to reduce the amount of angiotensin II in the blood. Cozaar is not associated with a significant cardiovascular risk, and it does not cause any clinically significant risk to a patient.
The authors conclude that "the increased cardiovascular risk observed in Cozaar patients may be due to the effects of the drug on the angiotensin II-type receptor."
Cozaar, like other antihypertensive drugs, is also associated with a small but significant risk of stroke, which is greater in elderly patients.
A
The American Heart Association recommends that the use of Cozaar be restricted to patients with severe hypertension and who are currently taking low-dose or no-dose beta-blockers. The use of Cozaar is associated with a greater risk of cardiovascular events.
A study published in the April issue ofCirculationfound that patients who were prescribed Cozaar were more likely to develop cardiovascular events than those who were not treated with the drug.
In a study published in the July issue of, researchers evaluated the cardiovascular risk associated with Cozaar, and found that patients treated with Cozaar had a reduced risk of cardiovascular events compared to patients who were not treated with the drug.
D
The investigators concluded that Cozaar is not associated with a risk of cardiovascular death in patients who had a history of coronary revascularization procedures. The authors also note that patients who had been treated for more than a year with Cozaar had a reduced risk of dying from coronary revascularization procedures compared to those who were treated with the drug.
E
A study published in the August issue ofThe Journal of Cardiologyfound that the use of Cozaar, like other beta-blockers, is associated with a reduced risk of stroke and heart attack in patients with diabetes mellitus, a known risk factor for cardiovascular disease.
A similar study published in the September issue of theAnnals of Internal Medicinefound that patients taking the drug had a reduced risk of cardiovascular events compared to those on placebo.
In a study published in the September issue of the, researchers analyzed the risk of angioplasty and non-arterial thrombotic bypass graft (NATG), which bypasses the main artery of the heart and is used for those with a history of heart attack or stroke.
The researchers concluded that the risk of cardiovascular events is increased in patients taking Cozaar, particularly when compared to those who were not taking the drug. This increased risk may be related to the drug's mechanism of action and/or to its side effects.
The investigators note that "the increased cardiovascular risk seen in Cozaar patients may be related to the drug's mechanism of action, which is to reduce the amount of angiotensin II in the blood."
According to the investigators, the increased risk is likely a result of Cozaar's ability to block the action of angiotensin II, which is a chemical in the blood that causes vasoconstrictors in the heart.
LONDON: Pfizer’s stock was up almost 40 per cent in Friday morning trading as the pharmaceutical company reported a 25 per cent profit to investors.
The drugmaker reported a 25 per cent profit to investors on its first quarter results for the second quarter of 2011, when it posted a $12.9 billion loss.
In an exclusive news release from the London Stock Exchange, the drugmaker said it will make a new generic version of its anti-impotence drug, cozaar, which will become available in March.
“We’re very pleased with the positive impact the new generic will have on the company’s bottom line,” David Edwards, the company’s head of health and family medicine, said in the release. “We expect to make a big impact in the next year or so, but we expect to see some major price cuts by 2011.”
A Pfizer spokesman, Tonynatal, said: “We are very pleased with the positive impact the new generic will have on the company’s bottom line.”
LONDON stocks have been trading as low as $30 on the New York Stock Exchange, while Londoncore stock has dropped more than 10 per cent this morning.
The stock closed at $26.41 on the Nasdaq Stock Options (SFO) index and at $28.18 on the S& P 500 index. The stock closed at $36.86 on the Nasdaq Stock Options (SFO) index.
Pfizer (NYSE: PFE) reported a 25 per cent profit to investors on the first quarter results for the second quarter of 2011, when it posted a $12.9 billion loss. The company said it was expecting a 25 per cent profit to investors in the next few months.The drugmaker said it will make a new generic version of its anti-impotence drug, cozaar, which will become available in March.
The company also said it will make a generic version of the popular heart drug, losartan, to compete with Pfizer’s blockbuster product, Viagra.
LONDON shares fell 1 per cent on the London Stock Exchange after the company’s stock closed at $26.42 on the Nasdaq Stock Options (SFO) index. The company said it will make a generic version of the popular heart drug, losartan, to compete with Pfizer’s blockbuster product, Viagra.
Pfizer (NYSE: PFE) posted a 25 per cent profit to investors on the first quarter results for the second quarter of 2011, when it posted a $12.9 billion loss.LONDON shares fell 1 per cent on the London Stock Exchange after the company’s stock closed at $26.41 on the Nasdaq Stock Options (SFO) index. The company said it will make a new generic version of its anti-impotence drug, cozaar, which will become available in March.The company said it will make a new generic version of the popular heart drug losartan, to compete with Pfizer’s blockbuster product, Viagra.
Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
Medicare CardNo MedicareConcession
$11.95
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
HealthylifeThis product contains different inactive ingredients, which require a prescription to be effective. While the specific inactive ingredients in this product may vary, they are listed below.
Cozaar, generically known as losartan, is a widely prescribed medication primarily for managing hypertension, heart conditions, and angina. Its active ingredient, Losartan, works by relaxing blood vessels and increasing the body’s oxygen supply, allowing for better blood circulation. This medication is particularly beneficial for those struggling with heart conditions and those dealing with kidney stones or chronic kidney disease. It can also be used to manage symptoms of angina and to relieve the discomfort associated with the chest pain caused by angina or heart conditions.
Cozaar is an antihypertensive medication, primarily prescribed to treat hypertension and angina. It works by relaxing blood vessels, increasing blood flow to the heart and lungs. This helps to lower blood pressure and improve the comfort and overall quality of life of those affected by these conditions.
Cozaar comes in two doses, 25 mg and 50 mg. Your healthcare provider will determine the appropriate dosage based on your health status and lifestyle. For instance, if you are taking the higher dose, the medication may be prescribed as a single tablet, while if you are taking 50 mg, the medication is prescribed as a multiple-dose tablet. It's important to follow the prescribed dosage closely and not exceed one dose.
Cozaar can start working within 30 minutes to one hour after taking it. However, it can take longer to show results if you take it after a heavy meal or after a light meal.
Like any medication, Cozaar can cause side effects. Common side effects include gastrointestinal upset, such as nausea and vomiting, or an increased heart rate. Less common but serious side effects include a high temperature, headaches, or dizziness. In rare cases, Cozaar can also cause other effects such as an increased sensitivity to sunlight or excessive sweating. It's important to discuss any concerns or potential side effects with your healthcare provider.
Cozaar should be taken once daily, starting on the third or fourth day of your menstrual cycle or as prescribed by your healthcare provider. The dosage may vary based on your condition and how severe it is, as well as other medications you're taking.
Before taking Cozaar, it's important to consult with your healthcare provider to determine if it's safe and appropriate for your condition. They may need to adjust your dosage or prescribe alternative medications, such as beta blockers or nitrates. It's important to follow your healthcare provider's instructions and to be aware of any potential interactions with other medications you're taking.
If you have kidney disease, liver disease, or heart failure, it's important to avoid taking Cozaar if you have any of these conditions:
If you have any of these conditions, it's crucial to consult your healthcare provider and follow their guidance. It's important to take Cozaar exactly as directed, and the effects may be noticeable.
It's crucial to follow your healthcare provider's instructions precisely to minimize the risk of unwanted side effects. Taking the medication at the same time each day is vital to maintain overall well-being.
Cozaar can be taken with or without food. However, it's important to note that Cozaar can interact with certain medications, so be sure to inform your healthcare provider about all your medications, including over-the-counter and herbal remedies, to avoid any potential interactions.
Stade de France Pharmacy